Current Topics / Immune and Inflammatory Issues

Immune and Inflammatory Issues

Tracks autoimmune, histamine, and chronic-inflammation topics that often blend real disease management with broad internet theories.

Active 4 tracked concerns 1 recent PubMed papers Updated March 27, 2026 at 9:01 AM

This is a fast-moving signal tracker, not a diagnosis page

These tracker pages blend recent EasyNIH search interest, NIH news-release matches, and recent PubMed publication activity. They refresh about once a day.

Jump to a tracked concern

Biologics and immune-targeted drugs

Building

People often search these because the treatment names are unfamiliar, the dosing is different, and the immune-system side effects sound intimidating.

EasyNIH matches 1 NIH news hits 1 PubMed papers
1 NIH news release matched this topic.
1 recent PubMed paper matched this topic.
infection risk context
how targeted these drugs really are
monitoring requirements
DrugsInflammation

Anti-inflammatory diet claims

Building

People want food-based control over inflammatory symptoms, but online diet plans often overpromise and oversimplify very different diseases.

EasyNIH matches 1 NIH news hits PubMed papers
1 NIH news release matched this topic.
extreme elimination diets
social-media certainty without diagnosis
nutrition gaps from overly strict rules
NutritionInflammation

Histamine intolerance and MCAS claims

Watch list

A lot of broad symptom clusters end up getting labeled as mast-cell or histamine problems online, even when the evidence is thin or the symptoms are nonspecific.

EasyNIH matches NIH news hits PubMed papers
This is still on the watch list, but the last daily refresh did not find a strong signal yet.
over-restriction of diet
self-diagnosis
supplement stacks sold as full treatment plans
ControversialAllergy

Low-dose naltrexone

Watch list

LDN keeps surfacing in chronic-pain and autoimmune communities because it is framed as low-risk and broadly helpful across many conditions.

EasyNIH matches NIH news hits PubMed papers
This is still on the watch list, but the last daily refresh did not find a strong signal yet.
off-label expectations
condition-specific evidence gaps
people treating it like a universal inflammation fix
DrugsPain